
IMPACT THERAP-B
07630 · HKEXYingpai Pharmaceuticals is dedicated to tdevelopment of innovative, targeted anticproprietary intellectual property rights,focus on the synthetic lethality mechanis
Calendrier de l'IPO
- OuvrirMay 05
- FermerMay 08
- Montant allouéMay 12
- PaiementMay 13
- ListeMay 13
Principaux faits
Prix d'émission
HKD 20.10
Frais d'entrée dans les mines
HKD 4,393.86
Actions émises
41.98M
Taille du lot
200
Augmentation totale
HKD 843.7M
Montant estimatif du plafond du marché
—
Allocation publique
10.0%
Placement international
90.0%
Aperçu des activités
Yingpai Pharmaceuticals is dedicated to tdevelopment of innovative, targeted anticproprietary intellectual property rights,focus on the synthetic lethality mechanis
Utilisation des produits
1、Approximately 51% or HK$398.37 million will be allocated to fund the ongoing and planned clinical development, regulatory approval and commercialization of the core product Senaparib;
2、Approximately 31% or HK$242.15 million will be used to finance the ongoing clinical development of key products IMP1734 and IMP9064;
3、Approximately 8% or HK$62.49 million will be allocated to the R&D activities of other pipeline assets, including IMP1707, IMP7068, IMP22, IMP25, IMP08, IMP13 and IMP10;
4、Approximately 8% or HK$62.49 million will be used for the development of R&D platforms and the expansion of the pharmaceutical pipeline;
5、Approximately 2% or HK$15.62 million will be applied to working capital and other general corporate purposes.
Dossier de suivi du promoteur
Intermédiaires et documents
Parrains
- 高盛(亞洲)有限責任公司
- 中國國際金融香港證券有限公司
Sous-traitants
- 高盛(亞洲)有限責任公司
- 中國國際金融香港證券有限公司
- 招銀國際融資有限公司
- 老虎證券(香港)環球有限公司
Prospectus PDF
Prospectus PDF →Investisseurs de pierres angulaires
- 南京生物医药谷建设发展有限公司及华泰资本投资
- 黄河投资有限公司
- 睿远基金
- First Quarter Moon OFC-Phecda Fund
- LAV Star Limited
- LAV Star Opportunities Limited
- Prosper High Holding Limited
- Worldwide Healthcare Partners LLC
Total
0
32.1% of placement
BBX ne participe pas au processus d'attribution d'un OPI énuméré sur cette page. Cette page n'est qu'à titre informatif et n'est pas un conseil en investissement.